If You Invested in Azenta, Inc. (AZTA)
Looking for the current price? See the AZTA quote & overviewWhat $1,000 or $10,000 in AZTA Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Nov 20, 2015 |
|---|---|---|---|---|
| $1,000 | $1,621 +62% | $407 -59% | $2,998 +200% | $4,305 +331% |
| $10,000 | $16,214 +62% | $4,073 -59% | $29,982 +200% | $43,050 +331% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-18. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for AZTA$1,000 Investment Over Time
AZTA vs S&P 500Year-by-Year Returns
AZTA annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015Nov 20 to Dec 31 | $11.31 | $10.68 | -5.6% | -5.6% |
| 2016 | $10.68 | $17.07 | +59.8% | +50.9% |
| 2017 | $17.07 | $23.85 | +39.7% | +110.9% |
| 2018 | $23.85 | $26.18 | +9.8% | +131.5% |
| 2019 | $26.18 | $41.96 | +60.3% | +271.0% |
| 2020 | $41.96 | $67.85 | +61.7% | +499.9% |
| 2021 | $67.85 | $103.11 | +52.0% | +811.7% |
| 2022 | $103.11 | $58.22 | -43.5% | +414.8% |
| 2023 | $58.22 | $65.14 | +11.9% | +476.0% |
| 2024 | $65.14 | $50.00 | -23.2% | +342.1% |
| 2025 | $50.00 | $33.26 | -33.5% | +194.1% |
| 2026Dec 31, 2025 to Nov 18 | $33.26 | $48.69 | +46.4% | +330.5% |
About Azenta, Inc.
Healthcare · NASDAQ
Azenta, Inc. (Nasdaq: AZTA), also known as Azenta Life Sciences, is a provider of life sciences solutions that help organizations bring breakthroughs and therapies to market faster. According to company disclosures, Azenta focuses on cold-chain sample management and multiomics services, supporting work in areas such as drug development, clinical research and advanced cell therapies for pharmaceutical, biotech, academic and healthcare institutions.
Azenta is headquartered in Burlington, Massachusetts, and reports that it has operations in North America, Europe and Asia. The company’s common stock trades on Nasdaq under the ticker symbol AZTA. Its activities place it within the broader manufacturing and technology ecosystem that supports the life sciences industry, with a particular emphasis on sample management infrastructure and genomic and other multiomics analysis.
Business focus and segments
Based on available information, Azenta organizes its operations around two primary areas: Sample Management Solutions and Multiomics.
- Sample Management Solutions – In public materials, Azenta describes a "full suite of reliable cold-chain sample management solutions" and references biorepository facilities and sample storage. The company highlights capabilities in secure storage and logistics for biological samples, including support for clinical and diagnostic research. Sample Management Solutions includes offerings such as sample storage and repository services, and the company has referenced biorepository operations, including a facility in Indianapolis, Indiana.
- Multiomics – Azenta states that it provides multiomics services, including genomic analysis. Through its GENEWIZ brand, the company delivers genomic sequencing services. Company disclosures reference activities such as next generation sequencing, gene synthesis and other genomic analysis services, which are reported within the Multiomics segment.
In financial reports, Azenta distinguishes between products and services revenue, with services including activities such as genomic services and sample storage, and products including items such as consumables and instruments that support sample management workflows. The company’s segment reporting identifies Sample Management Solutions and Multiomics as key contributors to revenue.
Sample management and cold-chain capabilities
Azenta emphasizes its role in cold-chain sample management, supporting the storage and handling of temperature-sensitive biological and chemical samples. Public statements describe a focus on reliable cold-chain solutions and biorepository services that help maintain sample integrity for research and clinical programs. The company notes that it provides secure storage of study samples and manages logistics for research collaborations, such as its partnership with the PRECEDE Foundation for early detection of pancreatic cancer.
Azenta’s sample management capabilities are positioned to support large-scale research initiatives and clinical programs that require long-term storage and tracking of biospecimens. The company highlights its "global biorepository network" in connection with collaborations and indicates that it manages sample storage for complex, multi-institutional research efforts.
Multiomics and genomic services
Through its Multiomics segment, Azenta offers genomic analysis services that support precision medicine and research. Company communications describe activities such as next generation sequencing and gene synthesis, and reference partnerships where Azenta, via GENEWIZ, provides genomic sequencing and data generation. These services are used in research programs focused on diseases such as kidney and cardio-kidney-metabolic conditions, as well as oncology-focused initiatives like the PRECEDE Foundation’s work in pancreatic cancer.
Azenta reports that growth in its Multiomics segment has been driven in part by increased revenue from next generation sequencing, while noting variability in other sequencing modalities such as Sanger sequencing and gene synthesis. The company positions its multiomics capabilities as part of a broader offering that combines sequencing, data generation and sample management.
Brands and global reach
Azenta states that it delivers and supports its products and services through a set of industry-recognized brands, including:
- GENEWIZ
- FluidX
- Ziath
- 4titude
- Limfinity
- Freezer Pro
- Barkey
These brands are associated with areas such as genomic services, sample management tools, informatics and cold-chain solutions, according to company descriptions. Azenta notes that its customer base includes top pharmaceutical and biotech companies, academic institutions and healthcare organizations globally, reflecting its presence across major life sciences markets in North America, Europe and Asia.
Corporate activity and portfolio
Azenta’s public disclosures show ongoing portfolio management and capital allocation decisions. The company announced a definitive agreement for the sale of its B Medical Systems business to THELEMA S.À R.L., describing this as a step toward simplifying its portfolio and prioritizing core capabilities. It has also authorized a share repurchase program, indicating a focus on returning capital to shareholders alongside investments in productivity, organic growth and selective mergers and acquisitions.
Financial updates highlight the performance of the Sample Management Solutions and Multiomics segments, with commentary on revenue trends, gross margin, adjusted EBITDA and operating expenses. Azenta has reported efforts to streamline its organization, improve cost execution and enhance productivity through what it calls the Azenta Business System.
Governance and shareholder engagement
Azenta files regular reports and proxy statements with the U.S. Securities and Exchange Commission. Its definitive proxy statement outlines matters such as the election of directors, advisory votes on executive compensation, amendments to equity incentive plans and the ratification of independent auditors. The company holds an annual meeting of shareholders, conducted in a virtual format according to recent proxy materials, and provides for voting by mail, telephone and internet.
The proxy statement also describes the structure of the Board of Directors, board committees, risk oversight, environmental, social and governance (ESG) considerations and executive compensation programs. These disclosures provide investors with information on how Azenta approaches governance, compensation and long-term value creation.
Role in the life sciences ecosystem
According to its public communications, Azenta positions itself as a partner to organizations engaged in high-impact life science research and development. By combining cold-chain sample management, biorepository services and multiomics capabilities, the company aims to support the development of diagnostics, therapies and precision medicine approaches. Its collaborations with foundations, medical centers and industry partners illustrate how its infrastructure and services are integrated into large-scale research programs.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Azenta, Inc. investment returns
How much would $1,000 invested in Azenta, Inc. be worth today?
If you invested $1,000 in Azenta, Inc. (AZTA) 10 years ago on 2016-11-21, your investment would be worth $2,998 as of 2026-11-18, a +199.8% price return without dividends, growing at a compounded rate of 11.6% per year (CAGR).
Has Azenta, Inc. outperformed the S&P 500?
Over the past 10 years, AZTA returned +199.8% compared to +231.7% for the S&P 500, underperforming the benchmark by 31.9 percentage points.
What is Azenta, Inc.'s average annual return?
The compound annual growth rate (CAGR) of AZTA’s share price over the past 10 years is 11.6%, without dividends. Individual years vary a great deal, and AZTA’s best recent full year was 2020 (+61.7%) while the worst was 2022 (-43.5%).
For informational and educational purposes only, not investment advice.